{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '1.3', 'List of Abbreviations and Definition of Terms', 'Abbreviations', 'ADC', 'Antibody-drug conjugate', 'AE', 'Adverse event', 'ALT', 'Alanine aminotransferase', 'ANA', 'Anti-nuclear antibodies', 'ANC', 'Absolute neutrophil count', 'aPTT', 'Activated partial thromboplastin time', 'ASCL1', 'Achaete-scute homolog 1', 'ASRO', 'American Society for Radiation Oncology', 'AST', 'Aspartate aminotransferase', 'AT', 'Aminotransferase', 'ATA', 'Anti-therapeutic antibody', 'ATC', 'Anatomical therapeutic chemical (codes)', '\u00df-hCG', 'Beta-human chorionic gonadotropin', 'BUN', 'Blood urea nitrogen', 'CBR', 'Clinical benefit rate', 'CDSM', 'Clinical Drug Supply Management', 'CFR', 'Code of Federal Regulations', 'CNS', 'Central nervous system', 'CR', 'Complete response', 'CRAC', 'Central Radiographic Assessment Committee', 'CRP', 'C-reactive protein', 'CSC', 'Cancer stem cell', 'CT', 'Computerized tomography', 'CTC', 'Circulating tumor cell', 'CTCAE', 'Common Terminology Criteria for Adverse Events', 'ctDNA', 'Circulating Tumor DNA', 'CYP3A4', 'Cytochrome P450 3A4', 'DILI', 'Drug-induced liver injury', 'DLL3', 'Delta-like protein 3', 'DLL3high', 'DLL3 high expression in tumor defined as > 75% tumor cells staining', 'positive according to the VENTANA DLL3 (SP347) IHC Assay', '17']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'DNA', 'Deoxyribonucleic acid', 'DOR', 'Duration of response', 'ECG', 'Electrocardiogram', 'ECOG', 'Eastern Cooperative Oncology Group', 'eCRF', 'electronic Case Report Form', 'EDC', 'Electronic data capture', 'ED SCLC', 'Extensive-stage disease small cell lung cancer', 'EFNS', 'European Federation of Neurological Societies', 'EGF', 'Epidermal growth factor', 'EORTC', 'European Organization for Research and Treatment of Cancer', 'EOT', 'End of Treatment', 'EQ-5D-5L', 'EuroQoL Five Dimensions Questionnaire', 'ESMO', 'European Society for Medical Oncology', 'ESR', 'Erythrocyte sedimentation rate', 'EU', 'European Union', 'FDA', 'US Food and Drug Administration', 'FSH', 'Follicle-stimulating hormone', 'GCP', 'Good Clinical Practice', 'Gy', 'Gray', 'HDPE', 'High-density polyethylene', 'HIPAA', 'Health Insurance Portability and Accountability Act', 'HR', 'Hazard ratio', 'ICF', 'Informed consent form', 'ICH', 'International Council for Harmonisation', 'IDMC', 'Independent Data Monitoring Committee', 'IEC', 'Independent Ethics Committee', 'IHC', 'Immunohistochemistry', 'IL', 'Interleukin', 'IMP', 'Investigational Medicinal Product', 'INR', 'International normalized ratio', 'IRB', 'Institutional Review Board', 'IRT', 'Interactive response technology', 'IUD', 'Intrauterine device', 'IV', 'Intravenous(ly)', '18']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'JSMO', 'Japanese Society of Medical Oncology', 'LCNEC', 'Large cell neuroendocrine cancer', 'LDH', 'Lactate dehydrogenase', 'LD SCLC', 'Limited-stage disease small cell lung cancer', 'LFT', 'Liver function test', 'LVEF', 'Left ventricular ejection fraction', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'MRI', 'Magnetic resonance imaging', 'MTD', 'Maximum tolerated dose', 'nAb', 'Neutralizing antibodies', 'NASH', 'Non-alcoholic steatohepatitis', 'NCCN', 'National Comprehensive Cancer Network', 'NCI', 'National Cancer Institute', 'NEUROD1', 'Neurogenic differentiation 1', 'NSAID', 'Non-steroidal anti-inflammatory drug', 'NSE', 'Neuron-specific enolase', 'NYHA', 'New York Heart Association', 'ORR', 'Objective response rate', 'OS', 'Overall survival', 'PBD', 'Pyrrolobenzodiazepine', 'PCI', 'Prophylactic cranial irradiation', 'PD', 'Progressive disease', 'PDX', 'Patient-derived xenografts', 'PET', 'Positron emission tomography', 'PFS', 'Progression-free survival', 'PK', 'Pharmacokinetics', 'PO', 'Per os (by mouth)', 'PR', 'Partial response', 'PRO', 'Patient reported outcome', 'PT', 'Prothrombin time', 'PTFU', 'Post-treatment follow up', 'q6wk', 'Every 6 weeks', 'RECIST', 'Response Evaluation Criteria in Solid Tumors', 'RF', 'Rheumatoid factor', '19']\n\n###\n\n", "completion": "END"}